ID

38234

Description

Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib; ODM derived from: https://clinicaltrials.gov/show/NCT02056080

Lien

https://clinicaltrials.gov/show/NCT02056080

Mots-clés

Versions (1)
  1. 30/09/2019 30/09/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

30 septembre 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Neoplasm NCT02056080

Anglais

Eligibility Breast Neoplasm NCT02056080

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
confirmed diagnosis of metastatic breast cancer her2-positive phenotype (confirmed by ihc 3 + or fish positive)
Description

Secondary malignant neoplasm of female breast HER2 Positive Immunohistochemistry | Secondary malignant neoplasm of female breast HER2 Positive FISH Positive

Type de données

boolean

Alias
UMLS CUI [1,1]
C0346993
UMLS CUI [1,2]
C2348909
UMLS CUI [1,3]
C0021044
UMLS CUI [2,1]
C0346993
UMLS CUI [2,2]
C2348909
UMLS CUI [2,3]
C0162789
UMLS CUI [2,4]
C1514241
older than 18 years
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
progressed to at least one prior treatment line for mbc with trastuzumab and / or lapatinib, either as monotherapy or in combination with chemotherapy or hormonal therapy schemes
Description

Prior Therapy Quantity Secondary malignant neoplasm of female breast | trastuzumab | lapatinib | Combined Modality Therapy | Chemotherapy | Hormone Therapy

Type de données

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0346993
UMLS CUI [2]
C0728747
UMLS CUI [3]
C1506770
UMLS CUI [4]
C0009429
UMLS CUI [5]
C0392920
UMLS CUI [6]
C0279025
having the patient's complete medical history that contains all lines antiher2 therapy treatment
Description

Medical History | Targeted Therapy HER2 Quantity

Type de données

boolean

Alias
UMLS CUI [1]
C0262926
UMLS CUI [2,1]
C2985566
UMLS CUI [2,2]
C0069515
UMLS CUI [2,3]
C1265611
being a patient who initiated the combination of trastuzumab and lapatinib between january 2005 and december 2011
Description

Initiation Lapatinib/Trastuzumab Regimen

Type de données

boolean

Alias
UMLS CUI [1,1]
C1704686
UMLS CUI [1,2]
C1541246
inform the patient and get the signature of the informed consent
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
not having phenotypic classification of the tumor by ihc or fish test for her2
Description

Absence Immunohistochemistry Neoplasm HER2 | Absence FISH Neoplasm HER2

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C0021044
UMLS CUI [1,3]
C0027651
UMLS CUI [1,4]
C0069515
UMLS CUI [2,1]
C0332197
UMLS CUI [2,2]
C0162789
UMLS CUI [2,3]
C0027651
UMLS CUI [2,4]
C0069515
being a patient with her2-negative phenotype(fish negative or ihc in range [0-2 +] without fish)
Description

Patient HER2 Negative FISH Negative | Patient HER2 Negative Immunohistochemistry

Type de données

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C2348908
UMLS CUI [1,3]
C0162789
UMLS CUI [1,4]
C1513916
UMLS CUI [2,1]
C0030705
UMLS CUI [2,2]
C2348908
UMLS CUI [2,3]
C0021044
being a patient who received the trastuzumab and/or lapatinib treatment (tl) in combination with chemotherapy
Description

Lapatinib/Trastuzumab Regimen | Chemotherapy | Combined Modality Therapy

Type de données

boolean

Alias
UMLS CUI [1]
C1541246
UMLS CUI [2]
C0392920
UMLS CUI [3]
C0009429
being a patient who, since january 2012, began tl therapy for metastatic disease.
Description

Lapatinib/Trastuzumab Regimen Neoplasm Metastasis | Start time

Type de données

boolean

Alias
UMLS CUI [1,1]
C1541246
UMLS CUI [1,2]
C0027627
UMLS CUI [2]
C1301880
Retour au début de la page

Similar models

Eligibility Breast Neoplasm NCT02056080

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Secondary malignant neoplasm of female breast HER2 Positive Immunohistochemistry | Secondary malignant neoplasm of female breast HER2 Positive FISH Positive
Item
confirmed diagnosis of metastatic breast cancer her2-positive phenotype (confirmed by ihc 3 + or fish positive)
boolean
C0346993 (UMLS CUI [1,1])
C2348909 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,3])
C0346993 (UMLS CUI [2,1])
C2348909 (UMLS CUI [2,2])
C0162789 (UMLS CUI [2,3])
C1514241 (UMLS CUI [2,4])
Age
Item
older than 18 years
boolean
C0001779 (UMLS CUI [1])
Prior Therapy Quantity Secondary malignant neoplasm of female breast | trastuzumab | lapatinib | Combined Modality Therapy | Chemotherapy | Hormone Therapy
Item
progressed to at least one prior treatment line for mbc with trastuzumab and / or lapatinib, either as monotherapy or in combination with chemotherapy or hormonal therapy schemes
boolean
C1514463 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,3])
C0728747 (UMLS CUI [2])
C1506770 (UMLS CUI [3])
C0009429 (UMLS CUI [4])
C0392920 (UMLS CUI [5])
C0279025 (UMLS CUI [6])
Medical History | Targeted Therapy HER2 Quantity
Item
having the patient's complete medical history that contains all lines antiher2 therapy treatment
boolean
C0262926 (UMLS CUI [1])
C2985566 (UMLS CUI [2,1])
C0069515 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Initiation Lapatinib/Trastuzumab Regimen
Item
being a patient who initiated the combination of trastuzumab and lapatinib between january 2005 and december 2011
boolean
C1704686 (UMLS CUI [1,1])
C1541246 (UMLS CUI [1,2])
Informed Consent
Item
inform the patient and get the signature of the informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Absence Immunohistochemistry Neoplasm HER2 | Absence FISH Neoplasm HER2
Item
not having phenotypic classification of the tumor by ihc or fish test for her2
boolean
C0332197 (UMLS CUI [1,1])
C0021044 (UMLS CUI [1,2])
C0027651 (UMLS CUI [1,3])
C0069515 (UMLS CUI [1,4])
C0332197 (UMLS CUI [2,1])
C0162789 (UMLS CUI [2,2])
C0027651 (UMLS CUI [2,3])
C0069515 (UMLS CUI [2,4])
Patient HER2 Negative FISH Negative | Patient HER2 Negative Immunohistochemistry
Item
being a patient with her2-negative phenotype(fish negative or ihc in range [0-2 +] without fish)
boolean
C0030705 (UMLS CUI [1,1])
C2348908 (UMLS CUI [1,2])
C0162789 (UMLS CUI [1,3])
C1513916 (UMLS CUI [1,4])
C0030705 (UMLS CUI [2,1])
C2348908 (UMLS CUI [2,2])
C0021044 (UMLS CUI [2,3])
Lapatinib/Trastuzumab Regimen | Chemotherapy | Combined Modality Therapy
Item
being a patient who received the trastuzumab and/or lapatinib treatment (tl) in combination with chemotherapy
boolean
C1541246 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
Lapatinib/Trastuzumab Regimen Neoplasm Metastasis | Start time
Item
being a patient who, since january 2012, began tl therapy for metastatic disease.
boolean
C1541246 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C1301880 (UMLS CUI [2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial